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Abstract
Background Chronic spontaneous urticaria (CSU) nega-
tively impacts patient quality of life and productivity and is
associated with considerable indirect costs to society.
Objective The aim of this study was to assess the cost
utility of add-on omalizumab treatment compared with
standard of care (SOC) in moderate or severe CSU patients
with inadequate response to SOC, from the UK societal
perspective.
Methods A Markov model was developed, consisting of
health states based on Urticaria Activity Score over 7 days
(UAS7) and additional states for relapse, spontaneous
remission and death. Model cycle length was 4 weeks, and
total model time horizon was 20 years in the base case. The
model considered early discontinuation of non-responders
(response: UAS7 B6) and retreatment upon relapse (re-
lapse: UAS7 C16) for responders. Clinical and cost inputs
were derived from omalizumab trials and published sour-
ces, and cost utility was expressed as incremental cost-
effectiveness ratios (ICERs). Scenario analyses included no
early discontinuation of non-responders and an altered
definition of response (UAS7\16).
Results With a deterministic ICER of £3183 in the base
case, omalizumab was associated with increased costs and
benefits relative to SOC. Probabilistic sensitivity analysis
supported this result. Productivity inputs were key model
drivers, and individual scenarios without early discontin-
uation of non-responders and adjusted response definitions
had little impact on results. ICERs were generally robust to
changes in key model parameters and inputs.
Conclusions In this, the first economic evaluation of
omalizumab in CSU from a UK societal perspective,
omalizumab consistently represented a treatment option
with societal benefit for CSU in the UK across a range of
scenarios.
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Key Points for Decision Makers
Chronic spontaneous urticaria (CSU) is a
dermatological disease associated with a detrimental
impact on patient quality of life and considerable
societal burden. Omalizumab currently represents
the only licensed treatment option for patients with
inadequate response to H1 antihistamines and is used
as an add-on therapy to standard of care (SOC) in
clinical practice.
A cost-utility analysis from the UK societal
perspective found omalizumab as add-on therapy to
SOC to be associated with increased quality-adjusted
life-years and increased costs relative to continued
SOC alone. The incremental cost-effectiveness ratio
for omalizumab was low (£3183 per QALY gained).
Although this finding was robust to a number of
sensitivity analyses, further research is needed to
establish accurate estimates of CSU remission and
efficacy of omalizumab retreatment.
1 Introduction
Chronic urticaria (CU) is a dermatological disease charac-
terised by the rapid appearance of itchy hives, angioedema,
or both, lasting for 6 weeks or more [1]. Approximately
0.5–1 % of the general population suffer from CU and over
60 % of cases are classed as chronic spontaneous (previ-
ously termed idiopathic) urticaria (CSU), in which no
obvious triggers can be identified [2, 3]. The average
duration of CSU is generally up to 5 years, although more
severe cases can last considerably longer [2, 4].
CSU most frequently affects patients between 20 and
40 years of age and, when uncontrolled by medication, can
have an underestimated impact on patient health-related
quality of life (HRQoL) [2, 3, 5, 6]. In addition to the
physical discomfort caused by CSU, the unpredictability of
attacks, disruption of sleep quality and cosmetic disfig-
urement can reduce patient productivity [2, 3, 7, 8]. There
are considerable indirect costs to society associated with
CSU and a recent study demonstrated the impact of CSU
on both absenteeism and presenteeism in employment and
education [9, 10].
The current international guidelines on the definition,
diagnosis and management of CU recommend second-
generation non-sedating H1 antihistamines as the first-line
treatment [1]; however, over half of patients have an
inadequate response to licensed dose H1 antihistamines
[11]. If symptoms persist, guidelines recommend increas-
ing H1 antihistamine dosage up to four times the licensed
dose [1]. Finally, if symptoms persist in the following
1–4 weeks, the guidelines recommend the addition of
omalizumab, ciclosporin A or montelukast [a leukotriene
receptor antagonist (LTRA)] as add-on therapy to the
increased dose of H1 antihistamines [1].
Omalizumab is a humanised anti-immunoglobulin (Ig) E
monoclonal antibody approved by the European Medicines
Agency in 2014 as an add-on therapy for the treatment of
CSU in adult and adolescent (C12 years) patients with
inadequate response to H1 antihistamines. In 2015, omal-
izumab underwent appraisal by the National Institute for
Health and Care Excellence (NICE) and the Scottish
Medicines Consortium (SMC) for patients with an inade-
quate response to standard of care (SOC) treatment, con-
sisting of updosed H1 antihistamines, H2 antihistamines
and/or LTRAs.
In this study, we assess the cost utility of omalizumab
compared with continued SOC in patients with moderate or
severe CSU with an inadequate response to SOC, from the
broad UK societal perspective. The only other economic
evaluation conducted specifically in CSU is a trial-based
cost-effectiveness study from the French societal perspec-
tive that also emphasises the significant impact of CSU on
patient HRQoL [12]. To the authors’ knowledge at the time
of submitting this research for publication, the research
presented here represents the first cost-utility analysis
conducted for CSU and the only economic evaluation
based on a decision analytic model for this indication.
2 Methods
2.1 Patient Population
The base-case analysis considered the population recruited
to the GLACIAL phase III randomised controlled trial
(RCT)—patients with moderate-to-severe CSU inade-
quately controlled on SOC [13]. This patient population is
in line with published guidance and UK clinician feedback
on the most appropriate position for omalizumab in the
treatment pathway [1, 14, 15]. A scenario analysis based on
two other phase III RCTs (ASTERIA I, ASTERIA II)
evaluated omalizumab in its broader, licensed population
of patients with an inadequate response to licensed doses of
H1 antihistamines.
2.2 Comparator
Continued SOC was the comparator for this economic
evaluation, and was reflected by the placebo arms of the
relevant omalizumab trials. In the base-case analysis, this
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was the placebo arm of the GLACIAL trial (in which
patients received updosed H1 antihistamines, H2 antihis-
tamines and/or LTRAs) [13]. This comparator was con-
sidered appropriate based on clinical feedback suggesting
that, prior to approval of omalizumab, CSU patients inad-
equately controlled on SOC may nonetheless continue to
be treated with this regimen due to an absence of alterna-
tive licensed options. The SOC comparator in the scenario
analysis considering omalizumab in its broader licensed
population was different, being represented by the placebo
arms of the ASTERIA I and ASTERIA II trials (in which
patients received licensed doses of H1 antihistamines) [16,
17].
2.3 Perspective
The analysis was performed from the societal perspective,
which included direct costs within the healthcare system
[National Health Service (NHS) and Personal Social Ser-
vices (PSS)] and indirect costs falling outside this (i.e.
productivity costs). A scenario analysis considered the cost
utility of omalizumab from the NHS/PSS perspective.
2.4 Time Horizon and Discounting
The starting age of patients in the model was 43 years,
corresponding to the mean age of patients in the GLACIAL
trial [13]. The base-case model was run over a 20-year time
horizon as it was anticipated that the majority of patients
would have entered spontaneous remission by 20 years
following symptom onset. In determining maximum
potential disease duration from the literature, a systematic
literature review (see electronic supplementary material)
found no primary studies providing estimates of remission
probabilities beyond 10 years; however, the assumed time
horizon was based on information from a review article by
Beltrani which provided estimates up to 25 years [4]. Both
costs and health effects were discounted at a rate of 3.5 %
[18, 19].
2.5 Model Structure
A de novo Markov model consisting of eight states that
captured the major characteristics of CSU was constructed
in Microsoft Excel 2010 (Microsoft Corporation, Red-
mond, WA, USA). In all three phase III trials of omal-
izumab, disease activity was measured using the Urticaria
Activity Score (UAS), a patient daily diary capturing
severity of itch and number of hives. This score was cal-
culated over 7 days (UAS7), giving a score from 0 (ur-
ticaria-free) to 42 (maximum itch and number of hives).
Five model health states were defined on the basis of UAS7
disease activity: ‘severe urticaria’ (UAS7 = 28–42),
‘moderate urticaria’ (UAS7 = 16–27), ‘mild urticaria’
(UAS7 = 7–15), ‘well-controlled urticaria’ (UAS7 = 1–6)
and ‘urticaria-free’ (UAS7 = 0). UAS7 is a recommended
outcome for assessing disease activity and is highly cor-
related with HRQoL measures in CSU [20–22]. Further-
more, previous research has demonstrated that these UAS7
score ranges represent an efficient way to describe CSU
health states [23]. The three additional model states con-
sisted of a ‘relapse’ state, a ‘spontaneous remission’ state
and an absorbing ‘death’ state (Fig. 1).
The model applied SOC as background therapy in both
model arms. In the omalizumab arm, patients received
omalizumab as add-on therapy; no additional therapy was
applied in the SOC arm, reflecting the phase III study
designs [13, 16, 17]. Model cycle length was 4 weeks,
consistent with the administration schedule of omalizumab.
Severe 
urticaria 
UAS7 28−42
Moderate 
urticaria
UAS7 16−27
Mild urticaria
UAS7 7−15
Well-controlled
urticaria
UAS7 1−6
Urticaria-
free
UAS7 0
Relapse
Spontaneous 
remission
Death
All states except 
Relapse and Death 
can transition to 
Spontaneous 
remission
All states can 
transition to Death
UAS7: Urticaria Activity Score over 7 days.
Fig. 1 Diagram of the Markov model structure
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During the initial treatment period of the model, patients
could move from their beginning ‘severe urticaria’ and
‘moderate urticaria’ states to any of the five UAS7 health
states every cycle, depending on treatment response. A
half-cycle correction was not applied as it was considered
uninformative due to the short cycle length and the
unpredictability surrounding patient transitions between
health states.
2.5.1 Response Assessment
At the week 16 assessment point, patients receiving oma-
lizumab could be classed as either non-responders or
responders (response defined as UAS7 B6). Non-respon-
ders at week 16 (those in ‘severe urticaria’, ‘moderate
urticaria’ or ‘mild urticaria’ health states) stopped receiv-
ing omalizumab and subsequently received background
SOC treatment only for the remainder of the time horizon.
Responders at week 16 (‘well-controlled’ or ‘urticaria-free’
health states) continued receiving omalizumab until week
24. Between weeks 16 and 24, the proportion of responders
to non-responders was held constant at the week 16 level;
responders were redistributed among the response health
states over this 8-week period according to data from the
GLACIAL trial. Therefore, week 16 responders were
assumed to maintain a state of response until at least the
end of the 24-week treatment course. Patients in the SOC
comparator arm were not assessed for response at 16 weeks
and were instead treated with 24-week courses of back-
ground medication throughout the model time horizon.
At 24 weeks, all patients still receiving omalizumab (i.e.
responders) were assumed to stop treatment with omal-
izumab and receive only background SOC. These prior
responders were then retreated upon relapse. This treatment
schedule reflected the unpredictable nature of CSU, which
may spontaneously resolve over time; in clinical practice
omalizumab would be administered for 24 weeks and then
withdrawn to monitor for potential spontaneous remission
(remaining symptom-free with no active treatment).
2.5.2 Relapse and Retreatment
The model incorporated relapse, defined as UAS7 C16 in
the base-case analysis, as per inclusion criteria used in
phase III trials of omalizumab [13, 16, 17]. Patients in the
‘mild urticaria’ (UAS7 = 7–15), ‘well-controlled urticaria’
(UAS7 = 1–6) and ‘urticaria-free’ (UAS7 = 0) health
states were at risk of relapse from week 24, when active
treatment with omalizumab was stopped and only SOC was
continued in all patients. Although classed as non-respon-
ders, patients in the ‘mild urticaria’ state were modelled to
be at risk of relapse because they had derived some benefit
and it could not be assumed that this would be maintained
upon discontinuation of omalizumab.
Upon relapse, prior responders to omalizumab (UAS7
B6 at 16 weeks) were assumed to be retreated with a
24-week course of omalizumab; prior non-responders were
not retreated and stayed on SOC for the model time hori-
zon. Patients undergoing retreatment were assumed to
respond in the same way as in their initial 24-week treat-
ment course. This was based on a retrospective analysis,
which showed that 25 CU patients had the same response
rate and adverse event rate upon retreatment with omal-
izumab as during their first course [24]. Thus, for patients
who continued to exhibit a pattern of response to omal-
izumab followed by relapse, omalizumab treatment was
modelled as intermittent 24-week courses, with length of
treatment break varying depending on time to relapse.
Patients in the SOC arm who relapsed after an initial
response continued to receive SOC and were subject to the
same probability of response as on initial treatment. As
patients in the model are continuously on SOC, the model
reflected this through a structural assumption of repeated
24-week SOC treatment cycles without treatment breaks.
2.5.3 Spontaneous Remission State
In addition to relapse, patients were also subject to a
treatment-independent probability of entering a ‘sponta-
neous remission’ health state (defined as UAS7 = 0).
Patients experiencing spontaneous remission were mod-
elled to remain disease-free and in a ‘spontaneous remis-
sion’ health state for the duration of the model time horizon
or until death.
2.5.4 Discontinuation of Omalizumab
The model accounted for discontinuation of omalizumab
due to lack of efficacy, adverse events or physician/patient
choice. Patients discontinuing omalizumab were treated
with background SOC only, and it was assumed that they
would not be retreated with omalizumab throughout the
model time horizon.
2.6 Clinical and Data Inputs
The distribution of patients across health states for the first
six model cycles was determined directly from GLACIAL
patient-level data. Three datasets using different imputa-
tion methods were available for the GLACIAL trial: the
base-case analysis was based on observed data; baseline
observation carried forward (BOCF) and last observation
carried forward (LOCF) datasets were explored in scenario
analyses. Health-state distributions for each model arm
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over the 16-week period up to the assessment point are
provided in Table 1 (data previously unpublished).
2.6.1 Relapse Probabilities
Relapse probabilities for patients receiving SOC (those in
the SOC arm or those who had discontinued omalizumab)
were determined for each health state from patient-level
data sourced from the 16-week follow-up period (weeks
24–40) of the GLACIAL trial (cumulative relapse pro-
portions are presented in the electronic supplementary
material; data previously unpublished). Patients entering
spontaneous remission during this time were excluded from
the denominator of the relapse probability calculation. In
the base case, a linear extrapolation of cumulative relapse
probabilities was used to calculate relapse rates for model
cycles beyond 40 weeks; under this extrapolation, all
responders had relapsed by 16 months. Exponential
extrapolation was explored as a scenario analysis. Under
this extrapolation assumption, some patients were not
predicted to have relapsed at 16 months after omalizumab
discontinuation. These patients were forced to transition to
the relapse state based on the longest duration of symptom
absence with omalizumab use in CSU reported in the lit-
erature [24].
2.6.2 Probabilities of Spontaneous Remission
Following a systematic literature review of the natural
history of CSU (see the electronic supplementary material),
a study by Nebiolo et al.1 was selected to model proba-
bilities of spontaneous remission in the base case, and the
data were best fitted by a log-logistic distribution [26, 27].
This study was considered the most appropriate source
based on the accuracy of its definition of the patient pop-
ulation, large patient population, the prospective study
design, long follow-up (5 years) and frequent follow-up
times.
2.6.3 Discontinuations and Losses to Follow-Up
Discontinuations were modelled for the omalizumab arm
only as patients were assumed to continually be on back-
ground SOC treatment unless they had entered remission.
Discontinuation risks were estimated from GLACIAL
patient-level data and the model assumed no retreatment of
discontinued patients upon relapse. In the base-case anal-
ysis, patients lost to follow-up in the GLACIAL study were
assumed to transition to the ‘moderate urticaria’ health
state, regardless of prior health state or treatment arm; this
assumption was based on the UAS C16 inclusion criterion
of the GLACIAL trial [13]. Model inputs for the proba-
bilities of discontinuation and loss to follow-up are pro-
vided in the electronic supplementary material. No CSU-
related mortality was assumed; all-cause natural mortality
was incorporated using annual mortality rates for each age
group from the UK Office for National Statistics life
tables [28].
2.6.4 Adverse Events
In the GLACIAL study, no meaningful differences in
adverse event rates between omalizumab and SOC were
observed [13]. Despite this, several adverse events were
conservatively included to capture any potential impact on
cost utility of omalizumab versus SOC. Adverse events
occurring with C1 % frequency in any treatment arm
within pooled data from the GLACIAL, ASTERIA I and
ASTERIA II trials, and occurring C2 % more frequently in
the omalizumab 300 mg arm than the SOC arm in this
pooled analysis, were included. Derivation of 4-week risks
1 A discrepancy between the details in the text and the Kaplan–Meier
curve in the Nebiolo et al. publication was identified and corrected by
the Southampton Health Technology Assessments Centre as part of
the NICE Technology Appraisal 339 [25]. The corrected values were
used in this evaluation.
Table 1 Distribution of patients across health states per 4-week cycle over the 16-week period up to response assessment (GLACIAL popu-
lation, observed)
Baseline Week 4 Week 8 Week 12 Week 16
OMA SOC OMA SOC OMA SOC OMA SOC OMA SOC
n 252 83 196 74 219 72 216 67 212 64
‘Severe urticaria’ (UAS7 = 28–42) (%) 71.0 61.4 20.9 29.7 18.3 30.6 11.1 28.4 9.4 26.6
‘Moderate urticaria’ (UAS7 = 16–27) (%) 29.0 38.6 20.1 40.5 13.7 31.9 13.9 29.9 10.4 26.6
‘Mild urticaria’ (UAS7 = 7–15) (%) – – 17.5 27.0 13.2 27.8 11.6 26.9 9.9 29.7
‘Well-controlled urticaria’ (UAS7 = 1–6) (%) – – 25.2 2.7 21.5 6.9 24.1 9.0 21.7 12.5
‘Urticaria-free’ (UAS7 = 0) (%) – – 16.2 0.0 33.3 2.8 39.4 6.0 48.6 4.7
Data previously unpublished
OMA omalizumab, SOC standard of care, UAS7 Urticaria Activity Score over 7 days
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of individual adverse events is provided in the electronic
supplementary material.
2.7 Health Outcomes
Health outcomes were measured in quality-adjusted life-
years (QALYs), with utilities for each of the five health
states (Table 2) based on a published mixed-effects
regression model constructed from pooled EQ-5D data
across the GLACIAL, ASTERIA I and ASTERIA II trials
(details in the electronic supplementary material) [29]. The
model also incorporated disutilities associated with indi-
vidual adverse events; these disutilities were small in
magnitude (see electronic supplementary material).
2.8 Costs
Direct healthcare costs incorporated within the model
included drug, administration and health state costs
(Table 3; further breakdown is provided in the electronic
supplementary material). Costs of adverse events (see
electronic supplementary material) were applied for the
duration of each 4-week model cycle. This is a conserva-
tive assumption as the adverse events included would
likely resolve in less than 4 weeks.
The cost of relapse was taken from the NHS National
Schedule of Reference Costs 2012–13 (inflated to May
2014), weighted based on single professional and multi-
professional non-admitted face-to-face follow-up outpa-
tient appointments across Allergy, Clinical Immunology
and Dermatology specialties [30]. Health-state costs were
based on prior 12-month resource utilisation observed for
patients in each current health state in the ASSURE-CSU
study, a non-interventional burden-of-illness study con-
ducted across seven countries (data applied from UK
centres only) [9, 31, 32].
The model considered the societal perspective by
incorporating productivity costs based on data from the
same ASSURE-CSU study (Table 4). This study reported
on the proportion of patients in employment (51.35 %) and
the average number of days of absenteeism and presen-
teeism by health state [9, 10]. Costs associated with
absenteeism and presenteeism were based on the human
capital approach and were calculated from average weekly
earnings data sourced from the Office for National Statistics
(£478.00) [33]. A 160-hour working month was assumed.
All costs were inflated to 2014 values where necessary,
using the UK Consumer Price Index for Outpatient Ser-
vices (May 2014) [34].
2.9 Model Outcomes
The model calculated total discounted costs and total dis-
counted QALYs for the two treatment arms. Results of the
cost-utility analysis were expressed as incremental cost-
effectiveness ratios (ICERs).
2.10 Scenario Analyses and Sensitivity Analyses
The following scenario analyses explored uncertainty of
structural assumptions within the model:
1. Altered definition of response.
2. Altered probability of response on retreatment.
3. Use of datasets based on different imputation meth-
ods (BOCF and LOCF).
4. Alternative extrapolation for relapse assumptions.
5. Alternative sources of spontaneous remission data [4,
35, 36].
6. An alternative assumption of CSU patients who
received omalizumab not requiring background med-
ications aside from the licensed dose of H1
antihistamines.
7. Consideration of a narrower NHS/PSS perspective.
8. Shorter (10-year) time horizon.
9. Cost utility of omalizumab in CSU patients with an
inadequate response to H1 antihistamines, matching
the licensed indication of omalizumab (using pooled
data from the ASTERIA studies).
10. Exploration of alternative stopping rules for
omalizumab.
One-way sensitivity analysis (OWSA) was conducted to
identify key drivers of model results, and probabilistic
sensitivity analysis (PSA) was performed (1000 iterations)
to assess the impact of combined uncertainty in model
parameters. Details of how parameters varied in OWSA are
provided in the electronic supplementary material.
Parameters and distributions for each input in the PSA are
provided in Tables 1, 2, 3 and 4. Correlation was main-
tained through use of a Dirichlet distribution for patient
health-state distribution, a single random number for util-
ities and a single random variable for cumulative relapse
risks over time.
Table 2 Health-state utility inputs
Variable Value (SD; distribution)
‘Severe urticaria’ (UAS7 = 28–42) 0.712 (0.31; Beta)
‘Moderate urticaria’ (UAS7 = 16–27) 0.782 (0.26; Beta)
‘Mild urticaria’ (UAS7 = 7–15) 0.845 (0.24; Beta)
‘Well-controlled urticaria’ (UAS7 = 1–6) 0.859 (0.24; Beta)
‘Urticaria-free’ (UAS7 = 0) 0.897 (0.25; Beta)
Data published by Hawe et al. [29]; ASTERIA II 28-week data
excluded [41]
SD standard deviation, UAS7 Urticaria Activity Score over 7 days
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2.11 Model Validation
The model structure was validated through iterative dis-
cussions with clinical experts from the UK and Germany
and a UK professor of health economics, some of whom
are authors on this paper. The model was further validated
for technical accuracy through extensive internal and
external review. Full details of model validation and
methods for gathering expert feedback are summarised in
the electronic supplementary material.
Table 4 Indirect costs (absenteeism and presenteeism)
Health state Number of days absent
per 4-week cycle
Mean (SD) cost of
absenteeism per
4-week cycle, £
Number of days impaired
work (presenteeism)
per 4-week cycle
Mean (SD) cost of
impaired work
(presenteeism)
per 4-week cycle, £
Mean
(SE)
Distribution
(alpha, beta)
Mean
(SE)
Distribution
(alpha, beta)
‘Severe urticaria’
(UAS7 = 28–42)
2.89 (1.94) Gamma (2.22, 1.30) 300.30 (637.12) 8.80 (1.67) Gamma (27.92, 0.32) 913.10 (546.43)
‘Moderate urticaria’
(UAS7 = 16–27)
2.94 (1.32) Gamma (4.93, 0.59) 304.60 (531.09) 7.57 (1.83) Gamma (17.12, 0.44) 785.60 (710.43)
‘Mild urticaria’
(UAS7 = 7–15)
0.07 (0.07) Gamma (1.00, 0.07) 7.20 (20.38) 5.50 (1.68) Gamma (10.72, 0.51) 570.70 (492.96)
‘Well-controlled urticaria’
(UAS7 = 1–6)
0.00 Undefined 0.00 0.00 Undefined 0.00
Assumed that 51.35 % of CSU patients are employed [PSA (alpha, beta): Beta distribution (38, 36 %)]. Weekly average earnings assumed to be
£478.00 (Office for National Statistics, May 2014), and monthly working hours assumed to be 160. The ASSURE-CSU study collected data on
symptomatic patients only. The model assumed no impact on absenteeism and presenteeism in the ‘urticaria-free’ state based on the results
observed for the ‘well-controlled urticaria’ health state
PSA probabilistic sensitivity analysis, SD standard deviation, SE standard error, UAS7 Urticaria Activity Score over 7 days
Table 5 Deterministic and mean probabilistic ICERs for omalizumab versus SOC—base-case analysis
Omalizumab SOC Incremental
cost, £
Incremental
QALYs
ICER
(£ per QALY)
Probability of omalizumab being
cost-effective (at stated WTP threshold)
Cost, £ QALYs Cost, £ QALYs £20,000 £30,000
Deterministic 36,372 12.2 35,729 12.0 643 0.202 3183 – –
Probabilistic 36,500 12.2 35,812 12.0 688 0.2 3566 95.4 % 100 %
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SOC standard of care, WTP willingness to pay
Table 6 Breakdown of costs accrued in the omalizumab and SOC arms
Type of cost Omalizumab, cost (£) SOC, cost (£) Incremental cost (£) Proportion of total absolute
increment (%)
Technology costs 9323 2061 7262 32.6
Administration costs 204 0 204 0.9
Monitoring costs 390 0 390 1.8
Adverse event costs 17 14 3 0.0
Other direct healthcare costs 12,440 4926 7513 33.8
Indirect healthcare costs 23,932 30,803 -6871 30.9
Total 36,372 35,729 643 100
SOC standard of care
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3 Results
3.1 Base-Case Results
In the base-case analysis, omalizumab was associated with
increased cost but also increased benefit (QALYs) com-
pared with SOC, with a deterministic ICER of £3183 per
QALY (Table 5). Table 6 presents a breakdown of the
costs associated with the omalizumab and SOC arms in the
analysis.
Results of the probabilistic model were consistent with
those of the deterministic model, with a mean probabilistic
ICER of £3395 per QALY. The scatterplot of probabilistic
results is presented in Fig. 2, and the probability of cost
effectiveness of omalizumab at different willingness-to-pay
(WTP) thresholds is presented in the cost-effectiveness
acceptability curve (Fig. 3).
3.2 One-Way Sensitivity Analyses
OWSA (Fig. 4) found the ICERs to be most sensitive
to assumptions regarding productivity inputs, with three
of the five biggest drivers of model results related to
productivity (productivity loss at work, number of
work days missed and percentage employed). Regard-
less of which input was varied, the ICERs still fell
below a WTP threshold of £20,000 per QALY for all
OWSAs.
3.3 Scenario Analyses
The results of scenario analyses exploring key structural
and parameter assumptions in the model are presented in
Table 7. Considering the narrower NHS/PSS perspective,
which excludes societal costs, the incremental costs of
omalizumab are substantially higher, leading to an ICER
of over £35,000 per QALY. By contrast, ICERs below a
£20,000 per QALY WTP threshold were consistently
demonstrated when evaluating alternative sources of
remission data, alternative relapse extrapolations and
different assumptions around omalizumab efficacy on
retreatment, among other scenarios. In addition, omal-
izumab was similarly found to be associated with low
ICERs, indicating a net societal benefit, when used at an
earlier stage of the treatment pathway in line with the
full licensed indication. Exploration of alternative stop-
ping rules for omalizumab found that the most cost
effective stopping rule for omalizumab is an early stop
for non-responders after four doses (16 weeks) (see
Table 8).
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4 Discussion
The cost effectiveness of omalizumab has previously been
evaluated by NICE and the SMC from an NHS/PSS per-
spective in the CSU patient population with an inadequate
response to SOC [25]. Given that CSU affects patients of
working age and has a demonstrable impact on absen-
teeism and work impairment, the societal perspective may
be more appropriate [9, 10]. The current analysis demon-
strates productivity inputs to be key model drivers, and
finds that omalizumab is of net societal benefit when
considering this broader perspective. This finding is robust
to exploration of uncertainty through PSA, OWSA and a
range of scenario analyses. While reimbursement decisions
in the UK are based on a narrower perspective, these results
highlight the potential impact on decision making of con-
sidering the societal perspective.
This model was developed in close collaboration with
clinicians and health economists, which supports the
validity of the model design. Patient-level data from the
high-quality GLACIAL RCT (as well as the ASTERIA
RCTs for scenario analysis) provided the source for several
model inputs and thus the model reflects observations from
these trials; for example, in reflecting the observation that
patients who received placebo in these trials nevertheless
experienced a response [13]. Furthermore, the model
structure allowed patients to ‘jump’ between UAS7 health
states, which accurately reflects the patient experience of
CSU as one of non-linear and unpredictable changes in
disease activity.
Other strengths of the analysis include the use of a
systematic literature review to determine probabilities of
spontaneous remission, a UK-based primary source of
productivity inputs and the use of NHS reference costs
appropriate to the UK perspective [9, 27, 30]. Furthermore,
health-state utility inputs were based on the well-estab-
lished EQ-5D questionnaire, collected from patients within
the trials and valued using an algorithm derived from
preferences of the UK general public [37].
A key limitation of the analysis is the lack of available
evidence to comprehensively evaluate all potential com-
parators with omalizumab. Treatment options are limited
for patients with inadequate response to SOC, with omal-
izumab representing the only licensed alternative to con-
tinuation of SOC. Nonetheless, in clinical practice,
ciclosporin might also be used to treat these patients [1].
Similarly, in the scenario analysis based on the ASTERIA I
and ASTERIA II trials, alternative comparator treatments
according to treatment guidelines could include ciclosporin
or LTRAs [1]; however, a systematic literature review
identified an insufficient evidence base to allow for inclu-
sion of these comparators [38].
The analysis was unable to capture some potentially
important elements of CSU and its treatment. One limita-
tion of the model structure is a potential insensitivity to
improvement in patient condition. Within the model,
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patients can experience a large improvement in UAS7
(e.g. moving from ‘severe’ to ‘mild’ urticaria) without
achieving a response, whereas a patient experiencing a
much smaller absolute improvement in UAS7 might be
considered a responder due to crossing the response
‘threshold’. The model is also unable to capture HRQoL
benefits that may arise from rapid onset of treatment
effects in time frames shorter than the model cycle length
of 4 weeks. Omalizumab has demonstrated a rapid onset
of action, the benefit of which may not be captured [13,
24]. Similarly, this analysis did not account for any
potential impact of omalizumab in reducing requirements
for concomitant steroids and immunosuppressants along-
side SOC. Real-world evidence has suggested the potential
Table 7 Scenario analyses
Scenario Omalizumab SOC Incremental
cost (£)
Incremental
QALYs
ICER
(£ per
QALY)Total
cost (£)
Total
QALYs
Total
cost (£)
Total
QALYs
Base case 36,372 12.20 35,729 12.00 643 0.202 3,183
Response defined as UAS7B16 36,904 12.22 35,729 12.00 1,174 0.221 5,304
Omalizumab re-treatment efficacy
5% of prior responders do not respond on re-treatment 36,551 12.18 35,729 12.00 822 0.177 4,635
Probability of response on re-treatment of prior
responders is the same as for initial treatment
37,252 12.11 35,729 12.00 1,523 0.108 14,099
Imputation methods
BOCF 38,215 12.16 37,302 11.87 914 0.293 3,116
LOCF 37,028 12.20 36,810 11.89 218 0.310 704
Exponential relapse extrapolationb 35,361 12.22 35,472 12.01 -110 0.212 Dominant
Alternative spontaneous remission source
Beltrani 2002 31,828 12.28 31,568 12.10 260 0.183 1,419
Toubi 2004 26,042 12.41 25,276 12.26 766 0.155 4,936
Van der Valk 2002a 49,271 11.91 49,124 11.67 147 0.244 601
Background medication sparing effect 34,886 12.20 35,729 12.00 -843 0.202 Dominant
Narrower perspective
(NHS/PSS)
12,440 12.20 4,926 12.00 7,513 0.202 37,218
Alternative time horizon (10 years) 29,926 7.11 29,220 6.93 706 0.187 3,777
Pooled ASTERIA I and ASTERIA II datac 27,048 12.47 26,495 12.36 554 0.120 4,631
BOCF baseline observation carried forward; ICER incremental cost-effectiveness ratio; LOCF last observation carried forward; NHS National
Health Service; PSS Personal Social Services; SOC standard of care; QALYs quality-adjusted life years; UAS7 Urticaria Activity Score over 7
days
a Numbers based on the CSU population reported in the Van der Valk publication; bExponential extrapolations do not reach 100% of patients.
Patients remaining in response at 16 months post treatment discontinuation are ‘‘forced’’ to relapse in this scenario; cFor this scenario, data from
the ASTERIA I and ASTERIA II trials was used in place of data from GLACIAL and the following parameters were altered: omalizumab
treatment stopped after 3 doses; exponential extrapolation of relapse used; Beltrani used as the source of remission data; observed data (no
imputation for missing data) used
Table 8 Exploration of alternative stopping rules with omalizumab
Scenario analysis exploring alternative
stopping rules for omalizumab
Total cost
(£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs
ICER
(£ per QALY)
SOC 35,729 –
Omalizumab with early stop for non-responders after one dose 35,933 12.124 204 0.125 1633
Omalizumab with early stop for non-responders after four doses (base case) 36,372 12.201 438 0.077 5710
Omalizumab with 6 months of treatment for all 36,642 12.206 270 0.005 52,235
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years, SOC standard of care
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for omalizumab to reduce requirements for these thera-
pies; if modelled, this would reduce costs in the omal-
izumab arm and further increase the net societal benefit of
omalizumab [39, 40].
Finally, presenteeism and absenteeism inputs were
based on Work Productivity and Activity Impairment
(WPAI) data from UK patients in the real-world
ASSURE-CSU study [32]. A strength of this source is
simultaneous collection of WPAI data alongside UAS7
scores, generating robust productivity estimates by health
state.The difference in mean presenteeism estimates for
‘mild urticaria’ and ‘well-controlled urticaria’ health
states might be interpreted as inconsistent with the similar
utility estimates for these two states. However, an analysis
reducing mean presenteeism in the ‘mild urticaria’ health
state to 0 did not meaningfully impact the ICER (£4758
per QALY).
4.1 Areas of Further Research
Spontaneous remission is a key feature of CSU; however,
reported remission rates vary [4, 26, 35, 36]. Although this
analysis attempted to account for this by exploring alter-
native sources of remission data, further research to
understand the ‘true’ rates of spontaneous remission (and in
the UK population specifically) are required. Larger, con-
trolled studies investigating the efficacy of omalizumab
upon retreatment, and further data sources for time to
relapse following discontinuation of omalizumab, would be
welcome as these represent key elements of the model
structure.
5 Conclusions
Omalizumab as an add-on therapy to SOC for patients with
an inadequate response to SOC represents a treatment
option with societal benefit to the UK compared with
continued SOC alone. This evaluation highlights the
importance of considering the appropriate perspective and
presents, to the authors’ knowledge, the first decision
analytic model for the health economic analysis of omal-
izumab in this indication. Finally, this research highlights
important areas for future research to further develop
modelling approaches for this burdensome condition.
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